Toll Free: 1-888-928-9744

Angina (Angina Pectoris) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Angina (Angina Pectoris) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2017, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1 and 1 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Angina (Angina Pectoris) - Overview Angina (Angina Pectoris) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Angina (Angina Pectoris) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Angina (Angina Pectoris) - Companies Involved in Therapeutics Development Angionetics Inc Juventas Therapeutics Inc Kuhnil Pharmaceutical Co Ltd Sanofi TSH Biopharm Corporation Ltd ViroMed Co Ltd XyloCor Therapeutics Inc Angina (Angina Pectoris) - Drug Profiles alferminogene tadenovec - Drug Profile Product Description Mechanism Of Action R&D Progress EG-011 - Drug Profile Product Description Mechanism Of Action R&D Progress JVS-100 - Drug Profile Product Description Mechanism Of Action R&D Progress KI-1007 - Drug Profile Product Description Mechanism Of Action R&D Progress ranolazine ER - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-407899 - Drug Profile Product Description Mechanism Of Action R&D Progress VM-202 - Drug Profile Product Description Mechanism Of Action R&D Progress XC-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Angina (Angina Pectoris) - Dormant Projects Angina (Angina Pectoris) - Discontinued Products Angina (Angina Pectoris) - Product Development Milestones Featured News & Press Releases May 08, 2017: FDA Grants Fast Track designation to XyloCor Therapeutics Lead Candidate XC001 Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease May 16, 2012: Ark Completes Dose Ranging Phase I Section Of Refractory Angina Clinical Study Nov 03, 2010: Cardium Awarded Grant Under QTDP Program Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform (EG011) In Phase I/IIa Trial Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Angina (Angina Pectoris), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H2 2017 Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics Inc, H2 2017 Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017 Angina (Angina Pectoris) - Pipeline by Sanofi, H2 2017 Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H2 2017 Angina (Angina Pectoris) - Pipeline by ViroMed Co Ltd, H2 2017 Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H2 2017 Angina (Angina Pectoris) - Dormant Projects, H2 2017 Angina (Angina Pectoris) - Dormant Projects, H2 2017 (Contd..1), H2 2017 Angina (Angina Pectoris) - Discontinued Products, H2 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify